Guidance Details Post-Approval Responsibilities for Generics
FDA has issued a draft guidance outlining post-approval responsibilities facing manufacturers of generic drugs, highlighting requirements ranging from adverse event reporting and drug shortage notifications to labeling updates, promotional material submissions and compliance with Risk Evaluation and Mitigation Strategies (REMS).
A major portion of the guidance focuses on pharmacovigilance requirements, reminding generic drug sponsors that they must maintain written procedures for monitoring, evaluating and reporting adverse drug experiences from all sources, including scientific literature, postmarketing studies and commercial use.
FDA stresses that ANDA holders are required to promptly investigate potential safety signals and submit periodic adverse event reports. Companies also must file annual reports summarizing new safety information that could affect a product's labeling, effectiveness or risk profile.
The agency points manufacturers to its recently revised March 2026 guidance on postapproval safety data reporting standards, reflecting FDA's continued emphasis on postmarket surveillance as a cornerstone of drug safety oversight.
The guidance also underscores FDA's heightened focus on drug shortages, a persistent issue across the pharmaceutical supply chain. Generic drug manufacturers are required to notify FDA of permanent discontinuances or manufacturing interruptions involving certain finished drug products or active pharmaceutical ingredients when those disruptions could lead to meaningful supply shortages.
FDA reiterated that generic drug sponsors have an ongoing obligation to ensure product labeling remains current and consistent with new safety and efficacy information. ANDA holders are expected to routinely monitor changes to the labeling of their reference listed drugs (RLDs) and update their own labeling when necessary. The guidance references FDA's January 2024 recommendations on revising generic drug labeling following changes to the branded reference product.
The agency also reminded manufacturers that promotional materials, including Web sites, brochures, advertisements and digital content, must be submitted to FDA at the time of first use. Sponsors may voluntarily seek FDA advisory comments on proposed promotional campaigns before launch.
Addotionally, the guidance highlights requirements related to REMS programs, which FDA may require when additional safeguards are needed to ensure a drug's benefits outweigh its risks. When a reference drug is subject to a REMS, generic versions generally must implement comparable risk-management measures. Depending on the product, these may include medication guides, patient education materials, restricted distribution systems, prescriber certification requirements or patient monitoring programs.
FDA also devoted several sections of the guidance to exclusivity provisions affecting generic drugs. The document explains how companies receiving Competitive Generic Therapy designations must notify FDA when commercial marketing begins in order to preserve eligibility for the program's 180-day exclusivity incentive. The agency also reiterates requirements for first generic applicants holding traditional Hatch-Waxman 180-day exclusivity to report first commercial marketing.
Additionally, FDA outlines procedures for situations in which approved generic products become subject to adverse patent court rulings after approval. In certain cases, the agency may convert a fully approved ANDA to tentative approval if a court determines that a patent has been infringed and orders delayed market entry.